Imunoterapija

Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. (otvara novi prozor)

Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS

Izvor‎: N Engl J Med 2017;376(9):836-47.

Indeks‎: PubMed 28249141

DOI‎: 10.1056/NEJMoa1609783

https://www.ncbi.nlm.nih.gov/pubmed/28249141 (otvara novi prozor)

Chimeric antigen receptor T cells for sustained remissions in leukemia. (otvara novi prozor)

Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA

Izvor‎: N Engl J Med 2014;371(16):1507-17.

Indeks‎: PubMed 25317870

DOI‎: 10.1056/NEJMoa1407222

https://www.ncbi.nlm.nih.gov/pubmed/25317870 (otvara novi prozor)

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. (otvara novi prozor)

Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA, Grupp SA

Izvor‎: N Engl J Med 2018;378(5):439-48.

Indeks‎: PubMed 29385370

DOI‎: 10.1056/NEJMoa1709866

https://www.ncbi.nlm.nih.gov/pubmed/29385370 (otvara novi prozor)

Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. (otvara novi prozor)

O'Hear C, Inaba H, Pounds S, Shi L, Dahl G, Bowman WP, Taub JW, Pui CH, Ribeiro RC, Coustan-Smith E, Campana D, Rubnitz JE

Izvor‎: Cancer 2013;119(22):4036-43.

Indeks‎: PubMed 24006085

DOI‎: 10.1002/cncr.28334

https://www.ncbi.nlm.nih.gov/pubmed/24006085 (otvara novi prozor)

Gemtuzumab ozogamicin reduces relapse risk in FLT3/ITD acute myeloid leukemia: a report from the Children's Oncology Group. (otvara novi prozor)

Tarlock K, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch BA, Sung L, Pollard JA, Aplenc R, Loken MR, Gamis AS, Meshinchi S

Izvor‎: Clin Cancer Res 2016;22(8):1951-7.

Indeks‎: PubMed 26644412

DOI‎: 10.1158/1078-0432.CCR-15-1349

https://www.ncbi.nlm.nih.gov/pubmed/26644412 (otvara novi prozor)

ONKOLOGIJA (PEDIJATRIJA)

Imunoterapija

srpski (latinica)

Imunoterapija

https://assetsnffrgf-a.akamaihd.net/assets/ct/1add6d1d93/images/syn_placeholder_sqr.png

Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. (otvara novi prozor)

Chimeric antigen receptor T cells for sustained remissions in leukemia. (otvara novi prozor)

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. (otvara novi prozor)

Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. (otvara novi prozor)

Gemtuzumab ozogamicin reduces relapse risk in FLT3/ITD acute myeloid leukemia: a report from the Children's Oncology Group. (otvara novi prozor)

Kontakt s lokalnim predstavnicima (OOB)

Medicinske informacije

Filmovi

Imunoterapija

Izaberi jezik

Podeli